Evidence map›Paper›PMID 25889650›Full record

ArticleMolecular cancer2015

Hedgehog Acyltransferase as a target in estrogen receptor positive, HER2 amplified, and tamoxifen resistant breast cancer cells.

Armine Matevossian, Marilyn D Resh

Open access · goldAbstract read
In one paragraph

Article in Molecular cancer, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.

0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed
2.6field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

34 citing papers in PubMed, 47 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Review
  6. Review
  7. Article
  8. Current Status of Hedgehog Signaling Inhibitors.Current topics in medicinal chemistry · 2024
    Review
  9. Review
  10. Review
  11. Article
  12. A Large-Scale Genome-Wide Gene-Gene Interaction Study of Lung Cancer Susceptibility in Europeans With a Trans-Ethnic Validation in Asians.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2022
    Article
  13. UHRF1 modulates breast cancer cell growth via estrogen signaling.Medical oncology (Northwood, London, England) · 2022
    Article
  14. Article
  15. PRKCI Mediates RadiosensitivityFrontiers in oncology · 2022
    Article
  16. Article
  17. Review
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Armine MatevossianCell Biology Program, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, Box 143, New York, NY, 10065, USA. matevosa@mskcc.org.
Marilyn D ReshCell Biology Program, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, Box 143, New York, NY, 10065, USA. reshm@mskcc.org.
Memorial Sloan Kettering Cancer Center · US

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4M
Palmitoylation of Hedgehog ProteinsR01GM057966 · NIGMS · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI RESH, MARILYN D · 1998 to 2011
$3.2M
Hedgehog Acyltransferase as a target in cancerR21CA186957 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI RESH, MARILYN D · 2014 to 2015
$420k
NCI NIH HHS CA186957NCI NIH HHS P30 CA008748NCI NIH HHS R21 CA186957NIGMS NIH HHS GM57966NIGMS NIH HHS R01 GM057966
6 · The paper itself

Abstract

backgroundHedgehog acyltransferase (Hhat) catalyzes the transfer of the fatty acid palmitate onto Sonic Hedgehog (Shh), a modification that is essential for Shh signaling activity. The Shh signaling pathway has been implicated in the progression of breast cancer.

methodsTo determine the functional significance of Hhat expression in breast cancer, we used a panel of breast cancer cell lines that included estrogen receptor (ER) positive, HER2 amplified, triple negative, and tamoxifen resistant cells. We monitored both anchorage dependent and independent proliferation of these cells following depletion of Hhat with lentiviral shRNA and inhibition of Hhat activity with RU-SKI 43, a small molecule inhibitor of Hhat.

resultsDepletion of Hhat decreased anchorage-dependent and anchorage-independent proliferation of ER positive, but not triple negative, breast cancer cells. Treatment with RU-SKI 43 also reduced ER positive cell proliferation, whereas a structurally related, inactive compound had no effect. Overexpression of Hhat in ER positive cells not only rescued the growth defect in the presence of RU-SKI 43 but also resulted in increased cell proliferation in the absence of drug. Furthermore, depletion or inhibition of Hhat reduced proliferation of HER2 amplified as well as tamoxifen resistant cells. Inhibition of Smoothened had no effect on proliferation, indicating that canonical Shh signaling was not operative. Moreover, Hhat regulated the proliferation of both Shh responsive and non-responsive ER positive cells, suggesting a Shh independent function for Hhat.

conclusionsThese data suggest that Hhat plays a critical role in ER positive, HER2 amplified, and hormone resistant breast cancer proliferation and highlights the potential promise of Hhat inhibitors for therapeutic benefit in breast cancer.

Indexed as

AcyltransferasesAntineoplastic Agents, HormonalBreast NeoplasmsCell Line, TumorCell ProliferationDrug Resistance, NeoplasmDrug Screening Assays, AntitumorErb-b2 Receptor Tyrosine KinasesEstrogen Receptor alphaFemaleGene AmplificationHedgehog ProteinsHumansLapatinibProtein TransportQuinazolinesAcyltransferasesAntineoplastic Agents, HormonalERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesESR1 protein, humanEstrogen Receptor alphaHedgehog ProteinsHHAT protein, humanLapatinibQuinazolinesSHH protein, humanTamoxifen

Identifiers

PMID25889650
PMCPMC4711017
OpenAlexW2097997048

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.